论文部分内容阅读
目的:观察以吡柔比星为主的联合化疗对初治急性白血病的疗效。方法:治疗组,61例初治的急性白血病患者,其中急性非淋巴细胞白血病(ANLL)43例,予TA方案化疗犤吡柔比星(THP)联合阿糖胞苷(Ara-C)犦,急性淋巴细胞白血病(ALL)18例,予VTLP方案化疗犤THP联合长春新碱(VCR)、左旋门冬酰胺酶(L-Asp)、强的松(Pred)犦;对照组,53例初治的急性白血病中ANLL36例,予DA方案化疗,ALL17例,予VDLP方案化疗犤两方案均以柔红霉素(DNR)代替THP犦。2个疗程后比较两组疗效。结果:治疗组2疗程的完全缓解(CR)率(81.97%)明显高于对照组(50.94%)(P<0.05),但两组的总有效率差异无显著性(P>0.05)。结论:以吡柔比星为主的联合化疗可作为初治急性白血病的有效治疗方案。
Objective: To observe the efficacy of pirarubicin-based combination chemotherapy on newly diagnosed acute leukemia. Methods: In the treatment group, 61 patients with newly diagnosed acute leukemia, including 43 cases of acute non-lymphocytic leukemia (ANLL), were treated with TA regimen combined with THP plus Ara-C, 18 cases of acute lymphoblastic leukemia (ALL) were given VTLP regimen 犤 THP combined with vincristine (VCR), L-Asp, Pred prednisone; control group, 53 cases of naive Acute leukemia in 36 cases of ANLL, to DA regimen chemotherapy, ALL17 cases, to VDLP regimen 犤 two programs are daunorubicin (DNR) instead of THP 犦. After two courses of treatment, the two groups were compared. Results: The complete remission (CR) rate of two courses was 81.97% in the treatment group (50.94%) (P <0.05). However, the total effective rate was not significantly different between the two groups (P> 0.05). Conclusion: The combination of pirarubicin-based chemotherapy can be used as an initial treatment of acute leukemia effective treatment.